SBFM About
Sunshine Biopharma, Inc. is a New York-based pharmaceutical company that develops and commercializes oncology and antiviral drugs, as well as science-based nutritional supplements. Their products include treatments for Coronavirus infections and anticancer drugs. The company was founded on August 31, 2006.
Recent News
Stock Split April 17th, 2024
5 Point Inspection by OnePunchman:
- Free Float shares: 953.39 K - Positive
- Cash & equivalents: 16.29 M - Positive
- Debt: 657.71 K - Positive
- Last Quarter Revenue: $7.68M - Positive compared to Cash in hand and Free Float
- Prescriptions Drugs are in the market - https://sunshinebiopharma.com/prescription-drugs/
Buy Alert done by Fibonacci retracement levels:
Price: $3.20
- Entire Position Stop Loss: $2.91
- 1st Take Profit: $5.30 (I would sell 50% of my holdings here) - Risk to Reward Ratio is x8
- 2nd Take Profit: $8.79 (I would sell 30% of my holdings here) - Risk to Reward Ratio is x21
- 3rd Take Profit: $10.25 (I would sell 20% of my remaining holdings here) - Risk to Reward Ratio is x27
Trade closed: stop reached
How to trade OnePunch ALGO Scalper watch this video youtube.com/watch?v=5dU82w5Xb0Q
Join my Discord community and get 0dte option and breakout stocks alerts discord.com/invite/km3GFGKcQ7
DM for a free 30-day trial.
Join my Discord community and get 0dte option and breakout stocks alerts discord.com/invite/km3GFGKcQ7
DM for a free 30-day trial.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
How to trade OnePunch ALGO Scalper watch this video youtube.com/watch?v=5dU82w5Xb0Q
Join my Discord community and get 0dte option and breakout stocks alerts discord.com/invite/km3GFGKcQ7
DM for a free 30-day trial.
Join my Discord community and get 0dte option and breakout stocks alerts discord.com/invite/km3GFGKcQ7
DM for a free 30-day trial.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.